Genentech’s phase II trial of GDC-0449 in combo with Avastin & chemotherapy in metastatic colorectal cancer fails to …
Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, announced topline results from a phase II clinical trial conducted by Roche and Genentech, Curis’ collaborator and a wholly owned member of the Roche Group, of GDC-0449, a first-in-class Hedgehog pathway inhibitor.

Read more on PharmaBiz